Both in Biotechnology
Prime Medicine vs Ginkgo Bioworks Holdings
Over the past year PRME returned +15.6% and DNA returned +0.5%; their daily moves had a correlation of 0.42.
PRME +15.6% DNA +0.5%Growth of $1, one year, split-adjusted
| Metric | PRME | DNA |
|---|---|---|
| Price | $4.97 | $11.65 |
| Market cap | $901.4M | $784.5M |
| Today | +9.23% | +8.27% |
| 1 month | +42.0% | −6.1% |
| 6 months | +45.7% | +15.6% |
| Year to date | +43.2% | +40.2% |
| 1 year | +9.0% | −8.9% |
| Revenue growth (YoY) | +3.5% | −48.5% |
| Gross margin | 100.0% | 91.5% |
| Net margin | −3649.0% | −231.7% |
| P/E (TTM) | — | — |
| Price / sales | 221.3× | 7.0× |
| Net cash | $95.1M | $302.2M |
| Dividend yield | — | — |
| Volatility (60d) | 112.8% | 128.9% |
| Short % of float | 34.4% | 18.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).